Nice insights into RA-ILD from @jeffsparks: - assoc (in Medicare): male, smoker, asthma/COPD, b/tsDMARDs, steroids - mortality risk? Yes, esp resp (sdHR 4.4), cancer - ACPA/lung inflamm related to RA-ILD? Yes, esp anti-filaggrin (aOR 3.08/log unit) #ACR20 ABST0489/0490 @RheumNow https://t.co/DGkNNPOcbd

Be sure to check this session with @CCalabreseDO and Dr. Gordon Lam on the role of IL6 in inflammation, RA, and CRS at 2 pm EST today! #ACR20 @RheumNow https://t.co/c4oX1tNeId

Is it time to change RA EULAR guidelines to reflect what we do? SEAM RCT showed withdrawal of MTX better than D/C etanercept in controlled RA. ETN alone =ETN+MTX. I vote to d/c the Rx that failed or by pt preference! Abstr#939 @RheumNow #ACR20 https://t.co/l9TNM3Gt0e

RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow and its Faculty.

Poll results are in... most chose upadacitinib followed by tofacitinib as their Jak-i of choice if insurance approval was not a factor in those that failed a bDMARD and remain on a cDMARD with high dz activity! @RheumNow @LCalabreseDO @ElaineHusniMD #ACR20 https://t.co/rl1nTqxzKg

• https://twitter.com/meralelramahimd/status/1324768543733407744

Dr Curtis presents SEAM-RA RCT of withdrawal of ETN or MTX in patients on combo therapy in sustained remission. 49.5% of ETN mono retained remission compared to 28.7% of MTX mono, and 52.9% who continued combo therapy. @rheumnow #ACR20 Abstr#939 #ACRbest https://t.co/wpAtBHJYUF

Important things to take note of re: HBV reactivation (risk stratification and RR) when we consider therapies for our RA pts. 👇 @RheumNow #ACR20 #MedTwitter https://t.co/ZJfnZHpmfw

Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ